Focusing on innovative biotherapies
to bring hope of cure to patients

We aspire to bring new and curative treatment in the fields of hematologic malignancies and autoimmune diseases

Integrated capabilities cross discovery and development to manufacturing and commercialization.

Diversified and balanced pipeline developed with a forward-looking, de-risked development approach.

Our leading and integrated platforms leverage advanced technologies that span the entire product lifecycle.

A mature and stable CMC platform enabling large-scale, high-quality manufacturing.

$IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma$